7-methoxy-2-methylbenzoxazole | 849402-66-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 7-methoxy-2-methylbenzoxazole
• 英文别名: 7-methoxy-2-methylbenzo[d]oxazole；Benzoxazole, 7-methoxy-2-methyl-；7-methoxy-2-methyl-1,3-benzoxazole
• CAS: 849402-66-0
• 化学式: C₉H₉NO₂
• 分子量: 163.176
• InChiKey: QFLAPOOXHSZHRZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  35.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  6-甲氧基-2-硝基苯酚 、 N,N-二乙基苯胺 反应 2.0h， 以42%的产率得到7-methoxy-2-methylbenzoxazole
  参考文献：
  名称：

  邻硝基苯酚和胺类合成苯并恶唑

  摘要：

  邻硝基苯酚和邻硝基苯胺在 210-215°C 与胺反应，分别以中等收率产生相应的苯并恶唑和苯并咪唑。研究了苯环上含有CO 2 Me 或OMe 基团的邻硝基苯酚与N,N-二乙基苯胺之间的反应，以研究这些取代基的位置和电子特性对恶唑环形成的影响。

  DOI：

  10.3987/com-04-s(p)11

文献信息

• N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
  申请人：Rodgers James D.

  公开号：US20100298334A1

  公开（公告）日：2010-11-25

  The present invention relates to N-(hetero)aryl-pyrrolidine derivatives of Formula I: which are JAK inhibitors, such as selective JAK1 inhibitors, useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

  本发明涉及式I的N-(杂)芳基吡咯烷衍生物： 这些是JAK抑制剂，如选择性JAK1抑制剂，在治疗JAK相关疾病方面具有用处，例如炎症和自身免疫性疾病，以及癌症。
• INHIBITORS OF CAMKK2 AND USES OF SAME
  申请人：New York University

  公开号：US20200369656A1

  公开（公告）日：2020-11-26

  The present disclosure provides compounds suitable for inhibiting CaMKK2. Also provided are compositions and methods of treating diseases associated with CaMKK2.

  本公开提供适用于抑制CaMKK2的化合物。还提供了与CaMKK2相关疾病的治疗方法和组合物。
• Inhibitors of interleukin-1beta converting enzyme
  申请人：Batchelor James Mark

  公开号：US20080039449A1

  公开（公告）日：2008-02-14

  The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-γ-mediated diseases and decreasing IGIF and IFN-γ production using the compounds and compositions of this invention. This invention also relates to methods for preparing-N-acylamino compounds.

  本发明涉及一种新型的化合物类别，其为白细胞介素-1β转化酶的抑制剂。本发明的ICE抑制剂具有特定的结构和物理化学特征。本发明还涉及包含这些化合物的制药组合物。本发明的化合物和制药组合物特别适用于抑制ICE活性，因此可以作为抗IL-1、凋亡、IGIF、IFN-γ介导的疾病、炎症性疾病、自身免疫性疾病、破坏性骨病、增生性疾病、感染性疾病、退行性疾病和坏死性疾病的药物。本发明还涉及使用这些化合物和组合物抑制ICE活性、治疗白细胞介素-1、凋亡、IGIF和IFN-γ介导的疾病、降低IGIF和IFN-γ的产生的方法。本发明还涉及制备N-酰基氨基化合物的方法。
• Inhibitors of interleukin-1 beta converting enzyme
  申请人：Bemis W. Guy

  公开号：US20080070953A1

  公开（公告）日：2008-03-20

  The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1 mediated diseases, including inflammatory diseases, autoimmune diseases and neurodegenerative diseases. This invention also relates to methods for inhibiting ICE activity and methods for treating interleukin-1 mediated diseases using the compounds and compositions of this invention.

  本发明涉及一种新型的化合物类别，它们是白细胞介素-1β转化酶的抑制剂。本发明的ICE抑制剂具有特定的结构和物理化学特征。本发明还涉及包含这些化合物的制药组合物。本发明的化合物和制药组合物特别适用于抑制ICE活性，因此可以作为对白细胞介素-1介导的疾病，包括炎症性疾病、自身免疫性疾病和神经退行性疾病的治疗药物。本发明还涉及使用本发明的化合物和组合物抑制ICE活性的方法以及治疗白细胞介素-1介导的疾病的方法。
• INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME
  申请人：Batchelor Mark James

  公开号：US20110178069A1

  公开（公告）日：2011-07-21

  The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-γ-mediated diseases and decreasing IGIF and IFN-γ production using the compounds and compositions of this invention. This invention also relates to methods for preparing N-acylamino compounds.

  本发明涉及一种新型化合物类别，其为白细胞介素-1β转化酶抑制剂。本发明的ICE抑制剂具有特定的结构和物理化学特征。本发明还涉及包含这些化合物的制药组合物。本发明的化合物和制药组合物特别适用于抑制ICE活性，因此可以优势地用作对抗IL-1、凋亡、IGIF和IFN-γ介导的疾病、炎症性疾病、自身免疫性疾病、破坏性骨病、增生性疾病、传染性疾病、退行性疾病和坏死性疾病的药剂。本发明还涉及使用本发明的化合物和组合物抑制ICE活性、治疗白细胞介素-1、凋亡、IGIF和IFN-γ介导的疾病、减少IGIF和IFN-γ产生的方法。本发明还涉及制备N-酰基氨基化合物的方法。